Evan Cantor, JD, MD

Director of Neuro-Oncology

Evan Cantor, JD, MD, is a Neuro-Oncologist in the Center for Cancer and Blood Disorders at Connecticut Children’s. Dr. Cantor’s clinical interests include low and high-grade intracranial neoplasms. In his free time, Dr. Cantor enjoys reading, spending time with his family, and Brazilian jiu-jitsu.

Education

Ben-Gurion University of the Negev Faculty of Health Sciences

Residency

NYU Langone Long Island formerly Winthrop-Univ Hos

Fellowship

University of Michigan Health System

  • American Board of Pediatrics - Pediatrics
  • American Board of Pediatrics - Pediatric Hematology-Oncology (Pending)

Assistant Professor of Pediatrics, University of Connecticut School of Medicine

  • View Dr. Cantor's bibliography
  • Cantor E, Koschmann C. “Multiplatform Molecular Profiling: A Precision Medicine Victory Built on Cytotoxic Chemotherapy” The Cancer Journal. 25(2):80, Mar 2019
  • Bruzek A, Ravi K, Muruganand A, Wadden J, Babila C, Cantor E, Tunkle L, Wierzbicki K, Stallard S, Dickson R, Wolfe I, Mody R, Schwartz J, Franson A, Robertson P, Muraszko K, Maher C, Garton H, Qin T, Koschmann C* (2020). Use of novel, hand-held, electronic DNA analysis platform to quantify multi-gene molecular response in CSF of patients with high-grade glioma. Clinical Cancer Research. 2020. DOI: 10.1158/1078-0432.CCR-20-2066
  • Pratt, D., Kumar-Sinha, C., Cieślik, M., Mehra, R., Xiao, H., Shao, L., Franson, A., Cantor, E., Chinnaiyan, A.M., Mody, R. and Abdullaev, Z., 2021. “A novel ATXN1-DUX4 fusion expands the spectrum of ‘CIC-rearranged sarcoma’of the CNS to include non-CIC alterations.” Acta Neuropathologica, 141(4), pp.619-622.
  • Cantor E, Wierzbicki K, Tarapore RS, Ravi K, Thomas C, Cartaxo R, Yadav VN, Ravindran R, Bruzek AK, Wadden J, John V, Babila CM, Cummings JR, Kawakibi AR, Ji S, Ramos J, Paul A, Walling D, Leonard M, Robertson P, Franson A, Mody R, Garton HJL, Venetti S, Odia Y, Kline C, Vitanza NA, Khatua S, Mueller S, Allen JE, Gardner S, Koschmann C. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro Oncol. 2022 Feb 6:noac030. doi: 10.1093/neuonc/noac030. Epub ahead of print. PMID: 35137228.
  • Cantor E, Meyer A, Morris SM, Weisenberg JLZ, Brossier NM. Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1. Childs Nerv Syst. 2022 Jun 1. doi: 10.1007/s00381-022-05571-y. Epub ahead of print. PMID: 35648241.

Locations Where I See Patients

Exterior view of Connecticut Children's Medical Center in Hartford

Connecticut Children’s Medical Center – Hartford

282 Washington Street
Hartford, CT06106
United States